Multi-event June 2025 FDA Recall Pitavastatin by Avkare

This Multi-event Class III drug recall was voluntarily initiated by Avkare on June 26, 2025 for the product Pitavastatin. The FDA reported the reason for recall as failed impurity/degradation specifications. The product was distributed Nationwide and the recall is currently ongoing.

Reported Recall Events

Recall Number: D-0529-2025

Reason for Recall
Failed Impurity/Degradation Specifications
Initiated
06-26-2025
Reported
07-09-2025
Quantity
8,573 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Nationwide in the USA
Pitavastatin Tablets, 2 mg, 90 Tablets per bottle, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478. NDC: 42291-906-90

Batch or Lot Expiration Information

Lot# Lot, expiry: Lot 46211, exp 10/31/2025; Lot 47683, exp 05/31/2026; Lot 46944 , exp 01/31/2026

Recall Number: D-0528-2025

Reason for Recall
Failed Impurity/Degradation Specifications
Initiated
06-26-2025
Reported
07-09-2025
Quantity
1,560 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Nationwide in the USA
Pitavastatin Tablets, 1 mg, 90 Tablets per bottle, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478. NDC: 42291-905-90

Batch or Lot Expiration Information

Lot# Lot, expiry: Lot 46208, exp 10/31/2025; Lot 47738, exp 09/30/2026; Lot 46943, exp 05/31/2026